# Inversago Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inversago-pharma

- Industry: Biotechnology
- Headquarters: Montréal, Canada
- Website: http://www.inversago.com
- Total disclosed funding: $111M
- Latest round: Series C (Oct 17, 2022)
- Investors on record: 12

## About

Inversago Pharma Inc., based in Canada, specializes in developing innovative therapies targeting metabolic and fibrotic diseases through the modulation of CB1 receptors.Founded in 2015 and headquartered in Montréal, Canada, Inversago Pharma Inc. focuses on developing therapies for metabolic disorders and fibrotic conditions. The company has successfully raised a total of USD 1,075 mn through multiple funding rounds, with its most recent funding being a Trade Sale on August 10, 2023, where Novo Nordisk A/S acquired Inversago Pharma for USD 1.075 billion. The company has completed a total of 4 deals to date under the leadership of CEO François Ravenelle.Inversago Pharma specializes in developing peripherally acting CB1 receptor (CB1r) blocker therapies aimed at addressing complications related to metabolic and fibrotic diseases. Its lead product, INV-202, is being evaluated in two Phase 2 clinical studies targeting diabetic kidney disease and obesity, aiming to regulate peripheral CB1 receptors linked to various metabolic conditions. The research pipeline also includes treatments for fibrotic conditions like pulmonary fibrosis and systemic sclerosis, primarily targeting healthcare providers and pharmaceutical partners in North America and Europe.Inversago Pharma's revenue model relies on collaborations and partnerships with larger pharmaceutical firms for the development and commercialization of its therapies. These collaborations typically involve milestone payments, royalties on product sales, and funding for research and development efforts, focusing on high-value therapeutic options that address significant unmet medical needs.Following the acquisition by Novo Nordisk A/S in August 2023, which was valued at USD 1.075 billion, Inversago Pharma plans to leverage this investment to bolster its clinical development pipeline, particularly in obesity and related disorders. The funds are expected to facilitate the progression of INV-202 and other compounds in development, with strategic initiatives aimed at expanding market reach in both established and emerging markets.

## Funding rounds

- Series C, Oct 17, 2022, $68M — New Enterprise Associates, Genesys Capital Management, Amgen Ventures, Forbion, adMare Bioinnovations, JDRF T1D Fund, AmorChem, Fonds de solidarite FTQ
- Series B, Sep 8, 2020, $36M — Genesys Capital Management, Forbion, adMare Bioinnovations, Fonds de solidarité FTQ Investissements, JDRF T1D Fund, AmorChem, AQC Capital
- Series A, Jul 25, 2018, $7M — Genesys Capital Management, Accel-Rx Health Sciences Accelerator, JDRF T1D Fund, Tarnagulla Ventures, AmorChem, AQC Capital

## Investors

- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Series A, Series B, Series C
- Accel-Rx Health Sciences Accelerator — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A, Series B, Series C
- Tarnagulla Ventures (https://capitalatlas.ai/funds/tarnagulla-ventures) — Series A
- AmorChem (https://capitalatlas.ai/funds/amorchem) — Series A, Series B, Series C
- AQC Capital (https://capitalatlas.ai/funds/aqc-capital) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series C
- adMare Bioinnovations (https://capitalatlas.ai/funds/admare-bioinnovations) — Series B, Series C
- Fonds de solidarité FTQ Investissements — Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series C
- Fonds de solidarite FTQ (https://capitalatlas.ai/funds/fonds-de-solidarite-ftq) — Series C